Outlook Therapeutics, Inc. Financial Ratios
OTLK|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -13.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-
Profit Margin
-5331.8%
Net Income / Revenue
Asset Turnover
0.08
Revenue / Total Assets
Equity Multiplier
-0.25
Total Assets / Equity
Profitability
Liquidity
Current Ratio
0.38
Quick Ratio
0.31
Solvency
Interest Coverage
21.79
Efficiency
Asset Turnover
0.08
Inventory Turnover
0.41
Days Sales Outstanding
385 days
As of FY2025 · SEC 10-K · Updated Jun 28, 2026
Earnings Quality
Accrual Ratio
-34.3%
-23.0pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.